Last $60.11 USD
Change Today +0.11 / 0.18%
Volume 5.7M
MRK On Other Exchanges
Symbol
Exchange
New York
Mexico
EN Paris
Sao Paulo
Frankfurt
As of 8:04 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK) Snapshot

Open
$60.42
Previous Close
$60.00
Day High
$60.42
Day Low
$59.83
52 Week High
08/27/14 - $60.58
52 Week Low
11/1/13 - $44.62
Market Cap
173.4B
Average Volume 10 Days
6.9M
EPS TTM
$3.49
Shares Outstanding
2.9B
EX-Date
09/11/14
P/E TM
17.2x
Dividend
$1.76
Dividend Yield
2.91%
Current Stock Chart for MERCK & CO. INC. (MRK)

merck & co. inc. (MRK) Details

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company’s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company’s Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi Pasteur S.A., and Sysmex Inostics GmbH. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

77,300 Employees
Last Reported Date: 02/27/14
Founded in 1891

merck & co. inc. (MRK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.2M
Executive Vice President and President of Glo...
Total Annual Compensation: $957.3K
Compensation as of Fiscal Year 2013.

merck & co. inc. (MRK) Key Developments

Pfizer Inc. and Merck & Co. Inc. to Collaborate on Study Evaluating Novel Anti-Cancer Combination Regimen

Pfizer Inc. and Merck & Co. Inc. announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's crizotinib (XALKORI(R)) with Merck's investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer.

Advaxis, Inc. and Merck Enter into Clinical Trial Collaboration Agreement

Advaxis, Inc. has entered into a clinical trial collaboration agreement with Merck, through its subsidiaries, to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck's investigational anti PD-1 antibody, pembrolizumab. The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer. Both ADXS-PSA and pembrolizumab are investigational members of a new class of cancer treatments known as immunotherapies that are designed to enhance the body's own defenses in fighting cancer. Preclinical evidence suggests that Advaxis Lm-LLO immunotherapies in combination with a PD-1 inhibitor may lead to an enhanced anti-tumor immune response. Under the terms of the agreement, Advaxis and Merck will collaborate to evaluate the ADXS-PSA/pembrolizumab combination as a treatment for prostate cancer. The Phase 1 part of the trial is designed to establish a recommended dose regimen for ADXS-PSA alone and combined with pembrolizumab, and the Phase 2 portion will assess the safety and efficacy of the combination. Advaxis will sponsor and fund the study and Merck will provide pembrolizumab. The companies will collaboratively oversee the conduct of the study, which is planned to begin in early 2015. Results from the study will be used to determine the path for further clinical development of the combination.

Merck & Co. Inc. Provides Updates on PNEUMOVAX

Merck provided the following statement regarding the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices' (ACIP's) updated pneumococcal vaccine recommendations for adults 65 years of age and older. These recommendations call for a two vaccine regimen utilizing a dose of the pneumococcal conjugate vaccine followed by a dose of Merck's PNEUMOVAX(R) 23, at an interval to be determined by the ACIP, in adults 65 years of age and older who have not previously received pneumococcal vaccine. ACIP also voted that these recommendations for routine use of the pneumococcal conjugate vaccine in adults 65 years of age and older should be reevaluated in 2018 and revised as needed. ACIP will continue to monitor disease trends and the impact of these new recommendations. PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F). PNEUMOVAX 23 (pneumococcal vaccine polyvalent) is approved for use in persons 50 years of age or older and persons aged two years and older who are at increased risk for pneumococcal disease. PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. Do not administer PNEUMOVAX 23 to individuals with a history of hypersensitivity reaction to any component of the vaccine. According to the National Foundation for Infectious Diseases, approximately 73 million adults in the United States have an indication for pneumococcal vaccination, but have not been vaccinated. It has been estimated that about 59 million working-age (18 to 64 years of age) adults at increased risk for invasive pneumococcal disease remained unvaccinated in 2009. However, vaccination rates have remained low at 20% in this population, according to the CDC's National Health Interview Survey in 2012. This vaccination rate is well below the Healthy People 2020 goals, which call for a pneumococcal disease vaccination rate of 60% for high-risk people between the ages of 18 and 64 years. Moreover, pneumococcal vaccination rates among adults aged 65 years of age or older also remained low at only 59.9% in 2012, versus the Healthy People 2020 target of 90%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:US $60.11 USD +0.11

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $107.56 USD +0.05
GlaxoSmithKline PLC 1,460 GBp -14.50
Pfizer Inc $29.39 USD +0.01
Roche Holding AG SFr.269.30 CHF +1.60
Sanofi €83.54 EUR +0.04
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 31.7x
Price/Sales 4.0x
Price/Book 3.6x
Price/Cash Flow 30.9x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.